Clinical Trial Update: Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 28 days of oral AZD2066 versus placebo for analgesic efficacy in painful diabetic neuropathy; the study is completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Painful Diabetic Neuropathy

Drugs mentioned

• AZD2066 (AZD2066)

Snippet

Sponsor: AstraZeneca | Conditions: Pain, Diabetic Neuropathy | Phase 2 | Status: COMPLETED | Results posted: 2012-10-29